Lexeo Therapeutics (LXEO) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Industry landscape and regulatory evolution

• Precision medicine adoption in cardiovascular disease is increasing due to evolving FDA requirements, now allowing biomarker-based endpoints for approvals.

• AAV vectors, particularly AAVrh10, are highlighted as the most efficient for cardiac gene delivery, outperforming alternatives like lipid nanoparticles and ASOs.

• Precision medicine remains underutilized in both cardiac and Alzheimer's disease, presenting significant opportunities for innovation.

Pipeline overview and clinical progress

• Two cardiac programs are in clinical stages: one for Friedreich's ataxia (FA) cardiomyopathy and another for plakophilin-2 arrhythmogenic cardiomyopathy, both showing promising biomarker and functional improvements.

• The Alzheimer's program targets APOE4 homozygotes, with a phase I study completed and data readout expected by end of 2024.

• All programs are at clinical stage, with ongoing or imminent data readouts.

Friedreich's ataxia cardiomyopathy program results

• Therapy demonstrated a well-tolerated safety profile and significant reductions in left ventricular mass index, lateral wall thickness, and troponin I at 12 and 18 months.

• Frataxin expression increased in cardiac tissue, with dose-dependent responses and up to 50% of heart cells transduced.

• Improvements in cardiac biomarkers were sustained or increased over time, suggesting disease modification.

• Regulatory alignment for pivotal study endpoints is expected by year-end.